iShares S&P Small-Cap 600 Growth

Most Recent

  • uploads///Tesla
    Consumer

    Is Tesla Bear Jim Chanos Buying Something New?

    Jim Chanos, the founder and president of Kynikos Associates, is a long-time short-seller of Tesla stock. Tesla stock has fallen 17.5% in the last year.

    By Rabindra Samanta
  • uploads///Shareholders
    Company & Industry Overviews

    Evercore’s Long-Term Commitment to Shareholders

    Evercore (EVR) has been very committed to rewarding its shareholders in the form of dividends as well as buybacks.

    By Raina Brown
  • uploads///Wealth mgt
    Company & Industry Overviews

    Evercore: Fall in Investment Management Revenues Continues

    Evercore’s (EVR) investment management revenue in 4Q17 fell 26% to $13.2 million compared to $18 million in 4Q16.

    By Raina Brown
  • uploads///Main
    Company & Industry Overviews

    Evercore in 4Q17: Tax Impact, Advisory Revenue, and More

    Evercore’s (EVR) revenues were $540 million in 4Q17, or 21% higher than 4Q16. Revenues of $1.7 billion for 2017 was 18% higher than 2016.

    By Raina Brown
  • uploads///MDXG _revenue growth
    Company & Industry Overviews

    Understanding MiMedx Group’s Zealous Focus on Sales

    MiMedx focuses on marketing efforts to increase revenues. The company has at its disposal a sales force of 320 professionals.

    By Kenneth Smith
  • uploads///VTS
    Company & Industry Overviews

    Sucampo Pharmaceuticals’ Amitiza: Its Competitive Landscape

    In the branded prescription category, Amitiza competes with Ironwood Pharmaceuticals (IRWD) and Allergan’s (AGN) Linzess.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Nektar Therapeutics: Positive Data from Phase 3 NKTR-181 Trial

    Nektar Therapeutics’ (NKTR) NKTR-181 has already received fast-track designation from the FDA (U.S. Food & Drug Administration).

    By Margaret Patrick
  • uploads///Petmed Risks
    Company & Industry Overviews

    Key Risks Facing PetMed Express in 2017

    PetMed Express (PETS) stock has risen 77% in the last one-year period, reaching a high of $50.06 on July 26, 2017.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Captisol-Enabled Prexasertib May Be Major Growth Driver for Ligand

    Eli Lilly’s (LLY) Captisol-enabled drug Prexasertib is currently being evaluated in multiple oncology indications such as head and neck cancer, small-cell lung cancer (or SCLC), and advanced metastatic cancer.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Fully Funded Partnerships May Drive Growth for Ligand Pharmaceuticals

    Ligand Pharmaceuticals (LGND) expects its licensees to invest ~$2.0 billion for advancing more than 155 partnered research and development programs in 2017.

    By Margaret Patrick
  • uploads///RV
    Basic Materials

    Flotek Industries’ Current Valuation versus Its Peers

    Sell-side analysts expect Flotek’s adjusted EBITDA to rise sharper in the next four quarters compared to its peers.

    By Alex Chamberlin
  • uploads///RV
    Miscellaneous

    Weighing Flotek’s Current Valuation against Peers

    Sell-side analysts expect FTK’s adjusted EBITDA to rise more sharply over the next four quarters than those of its peers.

    By Alex Chamberlin
  • uploads///RV
    Company & Industry Overviews

    How Flotek Industries Is Valued versus Peer Stocks

    Core Laboratories (CLB) is the largest company by market capitalization among our set of select oilfield services and equipment (or OFS) companies…

    By Alex Chamberlin
  • uploads///
    Company & Industry Overviews

    How Does Take-Two Interactive Software View Fiscal 2017?

    US-based Take-Two Interactive Software (TTWO) expects non-GAAP revenues in the range of $225 million–$260 million in fiscal 1Q17.

    By Adam Rogers
  • uploads///
    Company & Industry Overviews

    The Word on the Street: How Analysts See Papa John’s

    Analysts are maintaining a price target of $67.6 for Papa John’s for the next 12-months, which represents a return potential of 2.5% for the company.

    By Rajiv Nanjapla
  • uploads///BGSs  month Price Target and Recommendation
    Miscellaneous

    Why Are So Many Analysts Rating B&G Foods a ‘Hold’?

    Approximately 78% of analysts rate B&G Foods a “hold,” and 22% rate it a “buy.” None of the analysts rate it a “sell.”

    By Sushree Mohanty
  • uploads///BG Foods Revised EPS Estimates
    Miscellaneous

    Analysts Have Revised EPS Estimates for B&G Foods: Why?

    B&G Foods’ (BGS) earnings estimates have been on an upward trend since its fiscal 1Q16 impressive results. The Green Giant acquisition contributed to the results.

    By Sushree Mohanty
  • uploads///
    Company & Industry Overviews

    What Do Analysts Recommend for Texas Roadhouse?

    The rise in EPS estimates for the next four quarters has prompted analysts to increase their price target for TXRH for the next 12 months to $45.1 from their earlier estimate of $44.8.

    By Rajiv Nanjapla
  • uploads///Hormel Foods Annual Dividend Increased for Fiscal
    Earnings Report

    What Has Hormel Foods Planned for Fiscal 2016?

    Hormel Foods (HRL) announced a 16% increase in its annual dividend, effective fiscal 2016. The annual dividend is now raised to $1.16 per share to be paid in fiscal 2016.

    By Sushree Mohanty
  • uploads///Moving averages
    Macroeconomic Analysis

    What Are Analyst Recommendations for Vasco Data Security?

    Vasco Data Security (VDSI) has generated returns of -25.5% in the trailing 12 months and 3.0% in the trailing-one-month period.

    By Parker Thomas
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.